Adimab LLC is the leading technology provider for antibody-based drug discovery. Adimab focuses solely on its partners and does not pursue an internal product pipeline. Since 2009, Adimab has partnered with over 60 pharmaceutical and biotechnology companies. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly Merck, and Novo Nordisk. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Celgene, Genentech, Gilead, Kyowa Hakko Kirin, Novartis, Roche, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Alector, Cullinan Oncology, Dragonfly, Pliant, Potenza, Tizona, iTeos and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
For more information, please visit adimab.com.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The company is headquartered in Lund, Sweden, and has approximately 55 employees.
For more information, please visit alligatorbioscience.com.
Founded in 2016 as Shanghai Genechem Co. Ltd spin-off, Genbase Biotechnology Co., Ltd, is an innovative immunotherapy company with focus on developing cutting-edge gene, antibody and cellular therapies to address tremendous unmet medical needs in China and globally. By working closely with physicians in their leading fields, Genbase is developing novel therapies via leveraging physicians’ first-hand knowledge, clinical samples and database, and their experiences in clinical trials. Genbase, over 50 employees with expertise in immunotherapy, strives to become a leader with a strong pipeline of therapeutic approaches to significantly improve the quality of lives of our patients.
For more information, please visit genbase.com.cn.
TILT Biotherapeutics, founded in 2013, is developing a new treatment for cancer using oncolytic immunotherapy. Advanced solid tumors are difficult to treat with limited treatment options available. Preclinical data on TILT technology, alone and in combination with other immunotherapy agents (such as T- cells and checkpoint inhibitors) have demonstrated 100% cure rates. Company’s lead product (TILT-123) is now in Phase 1 clinical trials. Other clinical trials with TILT-123 in combination with checkpoint inhibitors or T-cell therapies are planned for the coming years.
For more information, please visit tiltbio.com.